UFPG
LAB icon

United Financial Planning Group’s Standard BioTools LAB Stock Holding History

United Financial Planning Group’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-250
Closed -$320 – 542
2025
Q4 		$320 Buy
+250
New +$336 ﹤0.01% 432

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

United Financial Planning Group's LAB Position: Q1 2026 in Review

United Financial Planning Group sold out of Standard BioTools (LAB) in Q1 2026, closing a stake of 250 shares — an estimated $320 sold.

United Financial Planning Group first reported a position in LAB in Q4 2025 and held it in 1 quarter. The position peaked at $320 in Q4 2025. 156 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • United Financial Planning Group reported no remaining Standard BioTools position as of Q1 2026 after selling out during the quarter.
  • United Financial Planning Group sold 250 Standard BioTools shares in Q1 2026, an estimated $320.
  • United Financial Planning Group first reported a position in Standard BioTools in Q4 2025 and held it in 1 quarter.
  • United Financial Planning Group's Standard BioTools position peaked at $320 in Q4 2025.
  • 156 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on United Financial Planning Group's 13F filing for Q1 2026, filed 8 May 2026.